The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...